CD4 Therapeutics is a Munich-based biopharmaceutical company advancing first-in-class immunotherapies to address autoimmune diseases with high unmet medical need. We focus on unlocking the therapeutic potential of regulatory T cells (Tregs) to treat conditions in which conventional biologics are insufficient or fail to provide durable benefit. Building on foundational discoveries in regulatory T cell biology, recognized by the 2025 Nobel Prize in Physiology or Medicine, we aim to translate these insights into meaningful therapies for patients.

Our lead candidate, Tregalizumab, is the only monoclonal antibody designed to selectively activate regulatory T cells (Tregs), offering a novel mechanism for immune modulation with the potential for significant clinical benefit across multiple autoimmune indications.

With worldwide exclusive rights to develop and commercialize Tregalizumab, CD4 Therapeutics combines cutting-edge science with a biomarker-driven clinical strategy, targeting indications such as oral lichen planus, lichen sclerosus, rheumatoide arthritis and acute graft-versus-host disease after stem cell transplantation, while planning expansion into broader autoimmune markets.

Founded in 2024 and led by a team with deep expertise over the past 25 years in immunology, drug development, and biotech leadership, our mission is to deliver transformative therapies that meaningfully improve patient outcomes and create compelling value for partners and investors.

CD4 Therapeutics

Org chart

Teams

Offices